The latest price target for Gain Therapeutics (NASDAQ:GANX) was reported by Chardan Capital on March 28, 2025. The analyst firm set a price target for $6.00 expecting GANX to rise to within 12 months (a possible 277.36% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Gain Therapeutics (NASDAQ:GANX) was provided by Chardan Capital, and Gain Therapeutics maintained their buy rating.

There is no last upgrade for Gain Therapeutics

The last downgrade for Gain Therapeutics Inc happened on August 19, 2022 when B. Riley Securities changed their price target from $11 to $5 for Gain Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gain Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gain Therapeutics was filed on March 28, 2025 so you should expect the next rating to be made available sometime around March 28, 2026.

While ratings are subjective and will change, the latest Gain Therapeutics (GANX) rating was a maintained with a price target of $6.00 to $6.00. The current price Gain Therapeutics (GANX) is trading at is $1.59, which is out of the analyst’s predicted range.